JP2015525572A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015525572A5 JP2015525572A5 JP2015526635A JP2015526635A JP2015525572A5 JP 2015525572 A5 JP2015525572 A5 JP 2015525572A5 JP 2015526635 A JP2015526635 A JP 2015526635A JP 2015526635 A JP2015526635 A JP 2015526635A JP 2015525572 A5 JP2015525572 A5 JP 2015525572A5
- Authority
- JP
- Japan
- Prior art keywords
- recombinant protein
- surfactant
- propanesulfonate
- sulfobetaine
- ammonio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 17
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 15
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 15
- 239000002888 zwitterionic surfactant Substances 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- 241000700605 Viruses Species 0.000 claims 7
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 claims 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 6
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 claims 6
- 239000000693 micelle Substances 0.000 claims 6
- 229940117986 sulfobetaine Drugs 0.000 claims 6
- 102000003390 tumor necrosis factor Human genes 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 5
- 108091006086 inhibitor proteins Proteins 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- 238000012258 culturing Methods 0.000 claims 3
- BHATUINFZWUDIX-UHFFFAOYSA-N Zwittergent 3-14 Chemical compound CCCCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O BHATUINFZWUDIX-UHFFFAOYSA-N 0.000 claims 2
- 230000004071 biological effect Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- ZIRURAJAJIQZFG-UHFFFAOYSA-N 1-aminopropane-1-sulfonic acid Chemical compound CCC(N)S(O)(=O)=O ZIRURAJAJIQZFG-UHFFFAOYSA-N 0.000 claims 1
- TUBRCQBRKJXJEA-UHFFFAOYSA-N 3-[hexadecyl(dimethyl)azaniumyl]propane-1-sulfonate Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O TUBRCQBRKJXJEA-UHFFFAOYSA-N 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- 241000714177 Murine leukemia virus Species 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261680039P | 2012-08-06 | 2012-08-06 | |
| US61/680,039 | 2012-08-06 | ||
| PCT/US2013/053781 WO2014025771A2 (en) | 2012-08-06 | 2013-08-06 | Methods and compositions for inactivating enveloped viruses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018190622A Division JP6833788B2 (ja) | 2012-08-06 | 2018-10-09 | エンベロープウイルスを不活化するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015525572A JP2015525572A (ja) | 2015-09-07 |
| JP2015525572A5 true JP2015525572A5 (enExample) | 2016-09-29 |
| JP6465800B2 JP6465800B2 (ja) | 2019-02-06 |
Family
ID=48986268
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526635A Active JP6465800B2 (ja) | 2012-08-06 | 2013-08-06 | エンベロープウイルスを不活化するための方法および組成物 |
| JP2018190622A Active JP6833788B2 (ja) | 2012-08-06 | 2018-10-09 | エンベロープウイルスを不活化するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018190622A Active JP6833788B2 (ja) | 2012-08-06 | 2018-10-09 | エンベロープウイルスを不活化するための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10188732B2 (enExample) |
| EP (2) | EP2879691B1 (enExample) |
| JP (2) | JP6465800B2 (enExample) |
| DK (1) | DK2879691T3 (enExample) |
| WO (1) | WO2014025771A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2879691B1 (en) | 2012-08-06 | 2019-03-27 | Biogen MA Inc. | Methods for inactivating enveloped viruses |
| WO2016044621A1 (en) * | 2014-09-17 | 2016-03-24 | Helixbind, Inc. | Methods and devices for detecting and identifying microorganisms |
| AR102198A1 (es) | 2014-10-09 | 2017-02-08 | Regeneron Pharma | Proceso para reducir partículas subvisibles en una formulación farmacéutica |
| US10605807B2 (en) | 2016-02-24 | 2020-03-31 | Bio-Rad Laboratories, Inc. | Methods and compositions for fluorescence detection |
| MX2019000935A (es) | 2016-08-16 | 2019-07-04 | Regeneron Pharma | Metodos para cuantificar anticuerpos individuales de una mezcla. |
| IL312194B1 (en) | 2016-10-25 | 2026-01-01 | Regeneron Pharma | Methods and systems for analyzing chromatography data |
| EP3446710A1 (en) * | 2017-08-25 | 2019-02-27 | Glenmark Pharmaceuticals S.A. | Methods of inactivating viral contaminants |
| AU2018331357A1 (en) | 2017-09-18 | 2020-04-02 | Bayer Healthcare Llc | Methods of inactivation of viruses using N-methylglucamides and its Derivatives |
| MX2020002850A (es) | 2017-09-19 | 2020-07-24 | Regeneron Pharma | Metodos para reducir la formacion de particulas y composiciones formadas a partir de estas. |
| WO2019086463A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| TWI853823B (zh) | 2018-07-02 | 2024-09-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| EP3880806A1 (en) | 2018-11-15 | 2021-09-22 | Bayer HealthCare, LLC | Viral inactivation methods for continuous manufacturing of antibodies |
| JP7788055B2 (ja) * | 2019-03-19 | 2025-12-18 | アムジェン インコーポレイテッド | ウイルス不活性化のための代替的界面活性剤 |
| CN110424030B (zh) * | 2019-08-30 | 2020-06-30 | 广州三孚新材料科技股份有限公司 | 无氰碱性电镀铜液及其制备和在挠性印刷线路板中的应用 |
| US20230183656A1 (en) * | 2020-05-14 | 2023-06-15 | Merck Patent Gmbh | Methods and compositions for purifying adeno associated virus particles or adenoviruses |
| US11643641B2 (en) | 2021-03-04 | 2023-05-09 | Malireddy S. Reddy | Prevention of viral transmission by naked genetic material |
| CN117836010A (zh) | 2021-06-21 | 2024-04-05 | 优尼科生物制药有限公司 | 改进的裂解程序 |
| WO2024115344A1 (en) | 2022-11-29 | 2024-06-06 | Merck Patent Gmbh | Method for inactivating enveloped viruses |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE242716C (enExample) | ||||
| DD242716A3 (de) * | 1981-08-28 | 1987-02-11 | Adw Der Ddr Inst F Chem Techno | Verfahren zur herstellung von gereinigten antigenen bzw. biopraeparaten |
| DE3704550A1 (de) * | 1987-02-13 | 1988-08-25 | Behringwerke Ag | Verfahren zur inaktivierung huellhaltiger viren in mittels einer zelle in vitro hergestellten protein-praeparationen |
| GB8927546D0 (en) | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
| US5314917A (en) | 1991-03-22 | 1994-05-24 | E. B. Michaels Research Associates, Inc. | Method for inactivating enveloped viruses and sperm |
| FR2805163A1 (fr) * | 2000-02-21 | 2001-08-24 | Pf Medicament | Utilisation d'un detergent de type zwittergent pour la preparation d'une composition pharmaceutique destinee a etre administree par voie nasale |
| US6635679B2 (en) * | 2001-05-14 | 2003-10-21 | Akzo Nobel N.V. | Methods and compositions for inactivating viruses |
| BRPI0417938A (pt) * | 2003-12-30 | 2007-04-17 | Wyeth Corp | formulações de proteìnas hidrofóbicas em uma composição imunogênica que possui tolerabilidade aperfeiçoada |
| PL1951299T3 (pl) * | 2005-11-04 | 2012-07-31 | Novartis Ag | Szczepionki przeciw grypie zawierające kombinacje adiuwantów cząsteczkowych i czynników wzmacniających immunogenność |
| EP1970440A1 (en) * | 2007-03-06 | 2008-09-17 | Qiagen GmbH | Polymerase stabilization by ionic detergents |
| US20120208982A1 (en) * | 2010-12-15 | 2012-08-16 | Baxter Healthcare S.A. | Viral Inactivation Using Improved Solvent-Detergent Method |
| GB201216121D0 (en) * | 2012-09-10 | 2012-10-24 | Novartis Ag | Sample quantification by disc centrifugation |
| EP2879691B1 (en) | 2012-08-06 | 2019-03-27 | Biogen MA Inc. | Methods for inactivating enveloped viruses |
-
2013
- 2013-08-06 EP EP13750235.7A patent/EP2879691B1/en active Active
- 2013-08-06 JP JP2015526635A patent/JP6465800B2/ja active Active
- 2013-08-06 EP EP18200752.6A patent/EP3456352A1/en active Pending
- 2013-08-06 DK DK13750235.7T patent/DK2879691T3/da active
- 2013-08-06 WO PCT/US2013/053781 patent/WO2014025771A2/en not_active Ceased
- 2013-08-06 US US14/419,968 patent/US10188732B2/en active Active
-
2018
- 2018-10-09 JP JP2018190622A patent/JP6833788B2/ja active Active
- 2018-12-06 US US16/211,302 patent/US10702603B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015525572A5 (enExample) | ||
| AU2017279583B2 (en) | Liquid Formulation Of Protein Conjugate Comprising The Oxyntomodulin And An Immunoglobulin Fragment | |
| JP2016539627A5 (enExample) | ||
| WO2013039861A3 (en) | Engineered nucleic acids and methods of use thereof | |
| WO2014164348A3 (en) | Modified caspase polypeptides and uses thereof | |
| WO2016070166A3 (en) | Messenger una molecules and uses thereof | |
| BR112015004696A2 (pt) | polipeptídeos quiméricos tendo especificidade de ligação alvejada | |
| WO2007098267A3 (en) | Pseudoinfectious flavivirus and uses thereof | |
| JP2015524422A5 (enExample) | ||
| WO2012018639A3 (en) | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures | |
| MX337936B (es) | Compuestos inhibidores del virus de la hepatitis c. | |
| PH12015500499A1 (en) | Recombinant measles virus expressing chikungunya virus polypeptides and their applications | |
| WO2011082388A3 (en) | Infectious dna vaccines against chikungunya virus | |
| JP2013517776A5 (enExample) | ||
| WO2011163628A3 (en) | Dengue virus (dv) polypeptide sequences, t cell epitopes and methods and uses thereof | |
| WO2012075379A3 (en) | Liquid viral formulations | |
| BR112013028679A2 (pt) | inibidores do vírus da hepatite c | |
| WO2008129971A1 (ja) | 改良された持続感染型センダイウイルスベクター | |
| WO2012075376A3 (en) | Lyophilized viral formulations | |
| WO2019088480A3 (ko) | 에티오나마이드를 이용한 줄기세포 이동성 향상 방법 | |
| WO2013104995A3 (en) | Compositions and methods for treating viral infections | |
| WO2012061248A8 (en) | Novel specific hcv ns3 protease inhibitors | |
| WO2012036391A3 (ko) | 돼지 써코바이러스２(ｐｃｖ２) 유전자의 표면발현용 벡터 및 이로 형질전환된 살모넬라 백신 균주 | |
| WO2012124978A3 (ko) | 3차원 세포배양으로 수득한 조정 배지를 유효성분으로 포함하는 허혈성 질환 치료용 약학적 조성물 | |
| WO2013044023A3 (en) | Citrus tristeza virus based vectors for foreign gene/s expression |